In addition, circNDUFB2 participates in the activation of anti-tumor immunity during NSCLC progression by activating the RIG-I–MAVS pathway (Li et al., 2021), indicating that circNDUFB2 inhibits NSCLC progression in a dual-role pattern. Here, MAVS is linked to non-small cell lung carcinoma.